

## **Emergency Preparedness Guidance**

### ***Update 10/21/21***

#### **Covid-19 Vaccination Boosters**

This is to identify when a dose is given as a booster to a fully vaccinated individual for the following products.

- Moderna
- Janssen (Johnson & Johnson)
- Pfizer

Submission Clarification Codes (SCC) 10 or 7 for the administration of a booster dose supported for COVID-19 claim reimbursement.

SCC 10 (Meets Plan Limitations)

SCC 7 (Medically Necessary)

## **Effective 1/15/2022 – COVID testing products**

CMS issued a press release on March 15, 2021 to announce an increase in payment for administering the COVID-19 vaccine. WellDyne has implemented this change for all vaccines administered to eligible members on or after March 15, 2021.

WellDyne is committed to the health and safety of our members by ensuring they have convenient access to COVID-19 vaccines and that pharmacies are appropriately reimbursed for administering them.

This is what you need to know about claim submission when administering COVID-19 vaccinations:

- Single-dose vaccines will be reimbursed \$40.00
- Multi-dose vaccines will be reimbursed \$40.00
- Regardless of dose number all pharmacies will be reimbursed \$40.00
- COVID-19 vaccinations are \$0.00 cost to the recipient
  - › Ingredient Cost and Gross Amount Due - \$0.00 or \$0.01
- Claim submission should follow industry standards for vaccination administration fee for service
  - › Professional Service Code “MA” (Medication Administered)
  - › Incentive Amount \$40.00
- Basis of Cost Determination “15” (free product or no associated cost)

## **Coverage of COVID-19 oral antiviral medication. FDA recently authorized two Covid-19 oral antiviral medication (for Emergency use only)**

### **About Covid-19 oral antiviral medications**

- On December 22, 2021, **Pfizer** received an Emergency Use Authorization (EUA) from the FDA for its oral antiviral therapy for COVID-19.
- On December 23, 2021, **Merck** received an Emergency Use Authorization (EUA) from the FDA for its oral antiviral therapy for COVID-19.
- The federal government will purchase all the initial supply and allocate the antiviral therapies to the states for distribution. During this time, the federal government will cover the ingredient cost of the COVID-19 oral antiviral, however, plan sponsors cover the dispensing fee.

### **WellDyne Program**

- Due to the acute nature of these therapies, WellDyne will provide a **program** that will allow COVID-19 antiviral drugs to process under the prescription benefit during the COVID-19 Public Health Emergency (PHE) to ensure eligible patients can readily access these drugs at available pharmacies.
- This includes a \$10 dispensing fee to pharmacies, which replaces the normal network dispensing fee
- **The Program will be operationalized for all WellDyne clients (excluding a few) as of End of day 1/7**

### **Program process**

- Pricing details
  - Zero-member cost
  - Zero ingredient cost
  - Reimburse \$10 dispensing fee to the pharmacy
  - DUR PPS fee (professional services fee)

### **COVID at-home test coverage**

#### **Program process**

- Zero-member cost
- \$10 per test reimbursement
- Quantity Allowed = 8 tests per 30 days
  - Call WellDyne for quantities exceeding 8 for members with physician prescription

Pharmacy Helpdesk: 888-886-5822